
Biogen’s controversial Alzheimer’s drug made $1.6M in revenue in June
NY Post
Biotech giant Biogen said Thursday that it brought in about $1.6 million in sales from its controversial Alzheimer’s drug last month after it was approved by the Food and Drug Administration earlier in June.
The drug, which is marketed as Aduhelm, is the first new treatment for Alzheimer’s in about 18 years and the first that doctors are hoping will not just lessen symptoms but target the underlying disease. The company said in its second-quarter earnings report that the drug, which was approved by the FDA on June 7, did $1.6 million in sales before the end of the quarter, which was June 30.More Related News

Gas prices reach highest level since October 2023 as oil holds above $100 per barrel; US stocks jump
Brent crude oil held above $100 per barrel on Monday, pushing national average gasoline prices to their highest level since October 2023 as President Trump urged allies to help protect oil tankers from Iranian attacks in the key Strait of Hormuz.












